Earnings Call Summary | ISpecimen(ISPC.US) Q4 2023 Earnings Conference
Earnings Call Summary | ISpecimen(ISPC.US) Q4 2023 Earnings Conference
The following is a summary of the ISpecimen Inc. (ISPC) Q4 2023 Earnings Call Transcript:
以下是iSpecimen Inc.（ISPC）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
ISpecimen reported an annual revenue of $9.93 million for the fiscal year 2023, a decrease from $10.4 million in 2022 due to an 11% decrease in the specimen count.
The average selling price per specimen increased from $378 to $404 due to a change in the specimen mix.
The cost of revenue rose slightly by 1% from $4.76M in 2022 to $4.82M in 2023.
They have increased annual expenditure on technology from $4.45 million in 2022 to $5.39 million in 2023, significantly investing in the development of their online marketplace.
Sales and marketing expenses increased by 15% in 2023 due to higher payroll, marketing expenses, and operating costs.
General and administrative expenses witnessed a decrease of 14% for the year ended.
iSpecimen报告称，由于样本数量减少了11％，2023财年的年收入为993万美元，低于2022年的1,040万美元。
由于样本组合的变化，每个样本的平均销售价格从378美元上涨到404美元。
收入成本从2022年的476万美元小幅增长了1％，至2023年的482万美元。
他们已将每年的技术支出从2022年的445万美元增加到2023年的539万美元，大量投资于在线市场的发展。
由于工资、营销费用和运营成本的增加，2023年的销售和营销费用增长了15％。
截至年底，一般和管理费用下降了14％。
Business Progress:
业务进展：
iSpecimen focused on technology advancements, including improved search functionality, increased automation, and matchmaking.
The company has improved its sales funnel speed and won rates with its matchmaking module and Next-Day Quote initiative.
They have progressed its cancer sequencing program, which aims to provide on-demand access to sequence biospecimens.
A new sales strategy has been launched focusing on team and line of business-oriented structures with a focus on key account management.
The company launched a partnership with TriMetis Life Sciences to standardize and enhance tissue sample evaluation.
Several marketing initiatives and realigned sales efforts resulted in considerable sales in December 2023, the highest in the company's history.
They have commenced a supplier contract refresh program to improve supplier engagement.
Plans to streamline operations, reduce costs and focus on key market opportunities in 2024 are in place.
ISpecimen entered an aftermarket offering agreement to sell shares of common stock up to $1.5 million for additional funding.
iSpecimen专注于技术进步，包括改进搜索功能、提高自动化程度和配对。
该公司通过其配对模块和次日报价计划提高了销售渠道速度和中标率。
他们已经推进了癌症测序计划，该计划旨在按需提供序列生物标本的访问权限。
已经启动了一项新的销售战略，该战略侧重于以团队和业务为导向的结构，重点是关键客户管理。
该公司与TrimeTis生命科学建立了合作伙伴关系，以标准化和加强组织样本评估。
多项营销举措和调整后的销售工作使2023年12月的销售额可观，创下公司历史最高水平。
他们已经启动了供应商合同更新计划，以提高供应商参与度。
2024年精简运营、降低成本和关注关键市场机会的计划已经制定。
iSpecimen签订了售后发行协议，出售不超过150万美元的普通股以获得额外资金。
More details: iSpecimen IR
更多详情： iSpecimen IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。